Induction of tolerance after combined immunosuppression and -adsorption in two patients with acquired haemophilia after severe haemorrhages controlled by sequential administration of rFVIIa and FEIBA.
Stockschläder
Marcus
M
University Medical Center Duesseldorf, Institue of Hemostasis and Transfusion Medicine, Moorenstr. 5, 40225 Duesseldorf, Germany. marcus.stockschlaeder@uni-duesseldorf.de
Ruf
Leilani
L
Linderer
Anne
A
Schroeder
Thomas
T
Knoefel
Wolfram T
WT
Haas
Rainer
R
Giers
Günther
G
Gerhardt
Andrea
A
Sucker
Christoph
C
Zotz
Rainer B
RB
Scharf
Rüdiger E
RE
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000628:therapy; D006470:Hemorrhage / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D007163:Immunosorbent Techniques; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D000069283:Rituximab
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001779:Blood Coagulation Factors; D004338:Drug Combinations; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D000069283:Rituximab; C103587:recombinant FVIIa; C065655:anti-inhibitor coagulant complex; D015942:Factor VIIa